Ge Long Hui·2026-03-31 15:27Core Viewpoints - China Biopharmaceutical reported a total revenue of 31.83 billion yuan for the year 2025, representing a year-on-year growth of 10.3% [1][2] - Adjusted net profit attributable to shareholders reached 4.541 billion yuan, a significant increase of 31.4% year-on-year; core net profit growth reached 15% when excluding factors like the Sinovac dividend [1][2] - The company’s innovative business showed strong performance, with revenue from innovative products growing by 26.2% year-on-year [1][2] - The internationalization strategy yielded significant results, highlighted by a $1.53 billion exclusive licensing agreement for the global FIC drug Rovaxitinib with Sanofi, marking the largest transaction in China's transplant field [1] Financial Performance - The company achieved a total revenue of 31.83 billion yuan in 2025, with a 10.3% increase compared to the previous year [1][2] - The adjusted net profit attributable to shareholders was 4.541 billion yuan, reflecting a 31.4% year-on-year growth [1][2] - The core product sales continued to grow, contributing to a robust financial position with ample cash reserves [1] Innovation and Product Development - The innovative business became the core growth engine, with innovative product revenue increasing by 26.2% year-on-year [2] - Anlotinib, a key product, benefited from the approval of three new first-line indications in 2025, leading to significant sales growth [2] - The company is focusing on several key clinical data releases in 2026, including results for LM-302 in first-line gastric cancer and TQB6411 in late-stage malignancies [8] Research and Development - The company is accelerating clinical progress in oncology, with multiple products showing FIC/BIC potential [3][4] - The small RNA business is developing a long-acting siRNA pipeline, with Kylo-11 showing significant potential in the cardiovascular field [4][5] - The company has established a comprehensive small RNA technology platform, laying the foundation for future product development and commercialization [5] Future Outlook - The company expects to achieve revenues of 35.782 billion yuan, 40.899 billion yuan, and 47.075 billion yuan from 2026 to 2028, with corresponding net profits of 3.591 billion yuan, 4.164 billion yuan, and 4.808 billion yuan [9] - The company maintains a "buy" rating based on its growth prospects and expected financial performance [9]